Amgen saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 70 to 78.
This exclusive rating from Investor's Business Daily identifies share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating north of 80 as they launch their largest price moves. See if Amgen can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Amgen is trying to complete a consolidation with a 346.85 entry. See if it can break out in heavy volume.
Amgen posted 13% EPS growth last quarter, while sales growth came in at 11%.
Amgen holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
